Biodexa Pharmaceuticals plc has announced the recruitment of the first patient in a Phase 2 study of Tolimidone for the treatment of Type 1 Diabetes. The clinical stage biopharmaceutical company, listed on Nasdaq under the ticker BDRX, is conducting the study as an Investigator Initiated Trial (IIT) at the University of Alberta Diabetes Institute. The trial aims to evaluate the effectiveness of Tolimidone by measuring C-peptide levels and HbA1c over a period of three months, initially involving 12 patients across three different dose groups. The study may be expanded at a later stage. Preclinical studies have shown Tolimidone's potential utility in Type 1 Diabetes, highlighting its ability to induce proliferation in beta cells, a key factor for beta cell survival and proliferation.